Mustafa Nevzat Amgen

What Mustafa Nevzat Amgen does

Amgen Turkey (Amgen İlaç Ticaret Limited Şirketi) is the Turkish sales and marketing subsidiary of Amgen Inc., the US-based independent biotechnology company. The subsidiary markets a portfolio of more than 15 branded biological medicines and biosimilars across five therapeutic areas: oncology and hematology (BLINCYTO, KYPROLIS, LUMAKRAS, VECTIBIX, MVASI), inflammation (AMGEVITA), bone health (EVENITY, PROLIA, XGEVA), cardiovascular (REPATHA), and nephrology (ARANESP, BEKEMV, NPLATE, PARSABIV, NEULASTIM). Customers are healthcare professionals, hospitals, and licensed pharmacies, with distribution handled through pharmaceutical wholesalers. The subsidiary operates with 11 employees from its Istanbul headquarters in Levent, began commercial presence through a distributor in 2005, and opened its direct office in 2010.

The portfolio is supported by the parent's biotechnology platforms. Amgen Inc. pioneers the use of living cells to produce biological medicines, leveraging recombinant DNA technology, monoclonal antibodies, biosimilars, multispecific drugs, and Generative Biology that combines AI and machine learning with protein drug discovery. Its deCODE subsidiary in Iceland provides genetic data analysis for target identification and validation. In Turkey, the subsidiary operates as a pharmaceutical field-sales enterprise targeting prescribers across all five therapeutic areas.

Amgen Turkey generates revenue through one-time prescription pharmaceutical product sales distributed via healthcare providers, hospitals, and pharmacies. Pricing is set at the parent-corporate level and is not publicly disclosed on the Turkish website. Product information documents (KUB/KT) for healthcare professionals and adverse-event reporting channels operate as part of the standard pharmacovigilance infrastructure. The subsidiary is legally a private limited company under Turkish law but is wholly owned by Amgen Inc., which is publicly traded on NASDAQ under ticker AMGN.

Name

Mustafa Nevzat Amgen

Legal name

Amgen İlaç Ticaret Limited Şirketi

Website

https://amgen.com.tr

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

11–50 employees

Short description

Amgen Turkey (Amgen İlaç Ticaret Limited Şirketi) is the Turkish sales and marketing subsidiary of Amgen Inc., commercializing more than 15 branded biologics and biosimilars in oncology, inflammation, bone health, cardiovascular, and nephrology to physicians, hospitals, and pharmacies across Turkey.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Biopharmaceutical products
• Biosimilar medicines
• Oncology therapeutics
• Monoclonal antibodies
• Biotechnology research

Headquarters

HQ city

Istanbul

HQ country

Türkiye

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Amgen generates revenue through the sale of prescription biopharmaceutical medicines. The company develops and markets treatments for serious illnesses including cancer, kidney disease, cardiovascular disease, inflammatory diseases, and bone health conditions. Products are distributed through healthcare providers, hospitals, and pharmacies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

Amgen Turkey develops, markets, and distributes a portfolio of innovative biopharmaceutical medicines and biosimilars for serious illnesses across five therapeutic areas: oncology and hematology, inflammation, bone health, cardiovascular disease, and nephrology. Its product range includes originator biologics (e.g., BLINCYTO, KYPROLIS, LUMAKRAS, REPATHA, PROLIA, EVENITY) and biosimilars (AMGEVITA, MVASI), leveraging Amgen's 40+ years of biotechnology expertise in producing biological medicines from living cells.

Product overview

Amgen Turkey operates as part of the global Amgen biotechnology company, with over 45 years of history and presence in more than 100 countries. The company offers a portfolio of innovative biopharmaceutical products and biosimilars across five therapeutic areas: Oncology and Hematology (BLINCYTO, KYPROLIS, LUMAKRAS, VECTIBIX, MVASI), Inflammation (AMGEVITA), Bone Health (EVENITY, PROLIA, XGEVA), Cardiovascular (REPATHA), and Nephrology (ARANESP, BEKEMV, NPLATE, PARSABIV, NEULASTIM). The portfolio includes both originator brand products and biosimilars (AMGEVITA, MVASI) developed leveraging Amgen's 40+ years of biopharmaceutical research, development, and manufacturing expertise. The company also operates the Amgen Science technology platform, which incorporates Generative Biology, AI/ML-driven protein drug discovery, genetic data analysis via deCODE, and adaptive clinical trial designs. Amgen Turkey's operations began via a distributor in 2005 and its headquarters opened in 2010.

Differentiator

Problem solved

Functional benefit

Brands

• Amgeneration: Young talent program for recent graduates in Turkey, offering rotation, global interaction, and social responsibility projects

Products and services

• AMGEVITA (adalimumab) Biosimilar of adalimumab (40mg/0.8ml and 20mg/0.4ml pre-filled syringe and pen formulations) used to treat autoimmune inflammatory conditions such as rheumatoid arthritis and psoriasis.
• ARANESP (darbepoetin alfa) Erythropoiesis-stimulating agent available in multiple dose strengths (10–150 mcg) as a pre-filled syringe injection solution for the treatment of anemia.
• BEKEMV (eculizumab) Monoclonal antibody infusion concentrate (300mg/30ml) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
• BLINCYTO (blinatumomab) Bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL).
• EVENITY (romosozumab) Sclerostin inhibitor monoclonal antibody (105mg/1.17ml) indicated for the treatment of osteoporosis in patients at high risk of fracture.
• KYPROLIS (carfilzomib) Proteasome inhibitor (60mg IV injection) indicated for the treatment of relapsed or refractory multiple myeloma.
• LUMAKRAS (sotorasib) KRAS G12C inhibitor (120mg film-coated tablet) indicated for the treatment of KRAS G12C-mutated non-small cell lung cancer.
• MVASI (bevacizumab) Biosimilar of bevacizumab available in 100mg/4ml and 400mg/16ml infusion concentrate formulations, used in the treatment of various cancers.
• NPLATE (romiplostim) Thrombopoietin receptor agonist available in 250mcg and 500mcg powder formulations for injection, indicated for the treatment of immune thrombocytopenia.
• NEULASTIM (pegfilgrastim) Long-acting granulocyte colony-stimulating factor (6mg/0.6ml pre-filled syringe) used to reduce the duration of neutropenia in patients receiving chemotherapy.
• PARSABIV (etelcalcetide) Calcimimetic agent available in 2.5mg/0.5ml, 5mg/1ml, and 10mg/2ml IV injection formulations for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
• PROLIA (denosumab) RANK ligand inhibitor (60mg/ml SC injection) indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture.
• REPATHA (evolocumab) PCSK9 inhibitor monoclonal antibody (140mg/ml pre-filled pen) indicated for the treatment of hypercholesterolemia and reduction of cardiovascular events.
• VECTIBIX (panitumumab) Anti-EGFR monoclonal antibody (20mg/ml in 5ml and 20ml vials) indicated for the treatment of wild-type RAS metastatic colorectal cancer.
• XGEVA (denosumab) RANK ligand inhibitor (120mg SC injection) indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
• Amgen Biosimilars Portfolio Portfolio of biosimilar medicines developed using Amgen's 40+ years of biopharmaceutical research, development, and manufacturing experience, providing treatment options across oncology, inflammation, and supportive care.

Quantifiable outcome

• Cardiovascular event reduction commitment: Goal to halve cardiovascular events by 2030
• +2 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Market position

Competitive moat5 records

Key highlights5 records

Customer concentration

• Xx.com/amgen_turkiye
• Facebookfacebook.com/amgenturkey
• LinkedInlinkedin.com/company/mustafa-nevzat-amgen
• Instagraminstagram.com/amgenturkiye

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mustafa Nevzat Amgen